Sheffield Telegraph; It will support their partnership with Aclipse Therapeutics to advance the translational development of M102 - a drug candidate for the treatment of motor neurone disease (MND).
Aclipse says M102 may also have potential to treat Friedreich’s ataxia, Huntington's disease and Parkinson's disease.
Mre info: